Localizing the sentinel node outside of the specialty center: Success of alymphatic mapping course in disseminating new technology

Citation
Ee. Zervos et al., Localizing the sentinel node outside of the specialty center: Success of alymphatic mapping course in disseminating new technology, ANN SURG O, 8(1), 2001, pp. 7-12
Citations number
12
Categorie Soggetti
Oncology
Journal title
ANNALS OF SURGICAL ONCOLOGY
ISSN journal
10689265 → ACNP
Volume
8
Issue
1
Year of publication
2001
Pages
7 - 12
Database
ISI
SICI code
1068-9265(200101/02)8:1<7:LTSNOO>2.0.ZU;2-S
Abstract
Background: Sentinel node biopsy (SNB) is an evolving technology in the man agement of breast cancer. The purpose of this study was to determine the su ccess of an SNB course in emphasizing principles fur participants to succes sfully initiate an SNB program at their institution. Methods: Participants in a university-sponsored course were queried 6 to 18 months after the course regarding their success in initiating SNB in their practice. Univariate analysis was used to determine the likelihood of impl ementing a SNB program. Results: Ninety-one participants responded. Of these respondents, 56 had in itiated an SNB program at their hospital, and 20 had completed a "validatio n" phase. "Validation" consisted of less than 10 cases for 11 respondents, 11 to 20 cases for 5 respondents, and 20 to 30 cases for 3 respondents and >30 cases for 1 respondent. Twenty-eight percent initiated the learning cur ve without an institutional Review Board (IRB) protocol, and a further 20% went on to utilize SNB without axillary dissection in sentinel node-negativ e patients without IRE approval. Univariate analysis revealed that surgeons practicing in a group whose caseload consisted of more than 25% breast sur gery cases were most likely (P < 0.05) to implement SNB in their practice. Conclusions: Success in applying SNB after a course is high among surgeons in groups with a significant breast caseload, although recommendations for obtaining institutional approval and completing a 30-case validation series are often disregarded.